Sekhri, Rohit
Sadjadian, Parvis
Becker, Tatjana
Kolatzki, Vera
Huenerbein, Karlo
Meixner, Raphael
Marchi, Hannah
Wallmann, Rudolf
Fuchs, Christiane
Griesshammer, Martin
Wille, Kai http://orcid.org/0000-0002-7682-8563
Funding for this research was provided by:
Universitätsklinikum der Ruhr-Universität Bochum
Article History
Received: 21 April 2021
Accepted: 16 August 2021
First Online: 31 August 2021
Declarations
:
: The questionnaire and study protocol for this retrospective study were approved by the Ethics Committee of the Ruhr-Universität Bochum, based in Bad Oeynhausen (Protocol file number #2020–704)<i>.</i>
: Informed consent was obtained from all individual participants included in the study.
: Patients gave informed consent regarding publication of their data.
: Martin Griesshammer: <u>Speaker´s bureau and Advisory Board: Amgen, AOP, Orphan, Novartis, Celgene, CTI, Shire, Pfizer, Roche, Janssen, Gilead, Astra Zeneca.</u>Kai Wille: <u>Advisory Boards and Congress fees: Amgen, Pfizer, Roche, Janssen, Novartis, BMS, Gilead, Shire.</u>All other authors declare that they have no conflict of interest or competing interests.